Safety of fecal microbiota, live-jslm (REBYOTA^™) in individuals with recurrent <i>Clostridioides difficile</i> infection: data from five prospective clinical trials.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CL received grants from Rebiotix Inc., a Ferring Company, Seres Therapeutics, and Summit Therapeutics for clinical trials. TL received grants from Rebiotix Inc, Seres Therapeutics, Summit Therapeutics and Finch Therapeutics. RO and ERD serve on the Rebiotix Physician Advisory Board. ERD received grants from Synthetic Biologics and Pfizer, and is a consultant for Pfizer, Merck, Seres Therapeutics, Summit Therapeutics, Ferring Pharmaceuticals and Abbott. PF is a consultant/advisory board member and speaker for Ferring Pharmaceuticals, Seres Therapeutics, and Takeda Pharmaceuticals and consultant for Merck & Co., Inc. LB, BG, and AH are employees of Rebiotix Inc., a Ferring Company. SK is a consultant/advisory board member for Ferring Pharmaceuticals, Takeda Pharmaceuticals, Niche Pharmaceuticals, and Immuron Ltd."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: These trials were sponsored by Ferring Pharmaceuticals."